Public health agency the US Food and Drug Administration reported on Monday that it has awarded accelerated approval to Polivy (polatuzumab vedotin-piiq), chemotherapy bendamustine and the rituximab combination for the treatment of adult patients with diffuse large
B-cell lymphoma (DLBCL) through its breakthrough and priority review designations.
M2 PHARMA-June 11, 2019-The US FDA approves the first chemoimmunotherapy regimen Polivy with BR for patients with relapsed or refractory diffuse large
B-cell lymphoma
Global Banking News-June 11, 2019-The US FDA approves the first chemoimmunotherapy regimen Polivy with BR for patients with relapsed or refractory diffuse large
B-cell lymphoma
NORDIC BUSINESS REPORT-April 2, 2019-Nordic Nanovector announces promising results from preclinical research collaboration to develop novel CD37-targeting alpha therapy for
B-cell tumours
A lymphoma which demonstrates transitional morphologic and immunophenotypic features between classical Hodgkin's lymphoma (CHL) and large
B-cell lymphoma (diffuse large B cell lymphoma and Burkitt's lymphoma), mostly presenting with a mediastinal but occasionally with a peripheral lymph node disease is termed as grey zone lymphoma (GZL) as shown in figure 2.1,2 The terms "gray zone or grey zone or unclassifiable or indeterminate or mediastinal grey zone lymphoma (MGZL)" are synonymous and are used interchangeably.3,4 The outcome of these cases may differ from DLBCL and CHL.5 These lymphomas may show three types of features:
Diffuse large
B-cell lymphoma (DLBCL) is the most common Non-Hodgkin lymphoma (NHL) and accounts for 30-40% of all NHLs [1].
Nonetheless, it can show a locally aggressive course if left untreated, (3,6,7) and rare transformation to diffuse large
B-cell lymphoma has been suggested.
In recent years, with the use of treatments containing rituximab in
B-cell lymphoma patients with HsAg positivity and resolved HBV infection, a serious increase in the rate of HBV reactivation has been observed (12).
Novartis' sBLA for Kymriah (tisagen lecleucel) suspension for intravenous infusion, has been accepted for Priority Review by the FDA for the treatment of relapsed or refractory diffuse large
B-cell lymphoma (DLBCL) in patients ineligible for or relapse after autologous stem cell transplant (ASCT).
Intravascular large
B-cell lymphoma (IVLBCL) is a rare
B-cell lymphoma involving and proliferating within small blood vessels and capillaries with sparing of large blood vessels [1].